Suchergebnisse - "Ma, Esprit"

PubPharm (22)

1

Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting

enthalten in: JCO oncology practice | 2024

von Vidal, G. | Jain, N. | Fisher, A. | +10

2

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes

enthalten in: The oncologist | 2024

von Stricker, T. | Jain, N. | Ma, E. | +15

3

Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents : Pre- versus post-VIALE-A real-world experience from a predominantly US community setting

enthalten in: Cancer medicine | 2023

von Vachhani, P. | Ma, E. | Xu, T. | +7

4

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer : experience from a large community oncology network in the USA

enthalten in: Future oncology (London, England) | 2023

von Schwartzberg, L. | Daniel, D. | Vaena, D. | +10

5

Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Gershon, A. | Ma, E. | Xu, T. | +7

6

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US

enthalten in: The oncologist | 2022

von Vachhani, P. | Flahavan, E. | Xu, T. | +10

7

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy : From a US Third Party Payer Perspective

enthalten in: PharmacoEconomics | 2022

von Pratz, K. | Chai, X. | Xie, J. | +6

8

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

enthalten in: PharmacoEconomics | 2022

von Pratz, K. | Chai, X. | Xie, J. | +6

9

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

enthalten in: PharmacoEconomics | 2022

von Pratz, K. | Chai, X. | Xie, J. | +6

10

Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective

enthalten in: PharmacoEconomics | 2022

von Pratz, K. | Chai, X. | Xie, J. | +6